New therapeutic approaches for SLE and lupus-like syndromes would be better directed on modifying Foxp3 expression by interfering with TLR7 activation or by blocking downstream effector cytokines such as IL-6. This evidence concerns the gene TLR7 and systemic lupus erythematosus.